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Abstract
Background: Nonhistone chromosomal proteins in concert with histones play important roles in
the replication and repair of DNA and in the regulation of gene expression. The deregulation of
these proteins can contribute to the development of a variety of diseases such as cancer. As a
nonhistone chromosomal protein, chromodomain helicase DNA binding protein 5 (CHD5) has
recently been identified as the product of a novel tumor suppressor gene (TSG), promoting the
transcription of p19ink4a and p16arf. The inactivation of CHD5 was achieved partly through genetic
deletion since it is located in 1p36, a region frequently deleted in human tumors. In this study, we
aim to study the involvement of CHD5 in gastric cancer, the second most common cancer
worldwide.
Methods: CHD5 expression in a panel of gastric cancer cells were determined by quantitative RT-
PCR. The methylation of CHD5 was evaluated by methylation specific PCR and bisulfite genome
sequencing. The effect of CHD5 on growth of gastric cancer cells was tested by colony formation
assay.
Results: CHD5 expression was down-regulated in all of gastric cancer cell lines used (100%, 7/7)
and significantly restored after pharmacological demethylation. Methylation of CHD5 promoter
was detected in all of seven gastric cancer cell lines and in the majority of primary gastric carcinoma
tissues examined (73%, 11/15). Finally, ectopic expression of CHD5 in gastric cancer cells led to a
significant growth inhibition.
Conclusion: CHD5 was a TSG epigenetically down-regulated in gastric cancer.
Background
All eukaryotic organisms have developed elaborate ways
of packaging DNA into chromatin through the dynamic
interactions of various DNA-associated proteins. Such
packaging is not only important for the storage of genetic
information with high fidelity and integrity, but also the
transfer of genetic information from DNA to RNA in a
tightly controlled manner. Proteins that bind to DNA to
form chromatin are traditionally divided into two general
classes: histones and nonhistone chromosomal proteins.
Histones are a group of highly conserved DNA binding
proteins and their various post-translational modifica-
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tions constitute the 'histone code' that guides the packag-
ing of DNA or chromatin remodeling. The histone code is
initiated, maintained and interpreted largely by nonhis-
tone chromosomal proteins [1-4]. For example, the
acetylation of lysine residues on histone tails by histone
acetyltransferases (HATs) neutralizes their charge and
decreases the affinity of histones with DNA, making DNA
accessible for transcriptional factors to initiate gene tran-
scription. Conversely, the deacetylation of these residues
by histone deacetylases (HDACs) restores this affinity and
can withdraw DNA from transcriptional machinery [5]. In
addition to acetylation, phosphorylation and methylation
of histone tails are important for the dynamic association
of DNA with transcriptional machinery and other chro-
mosomal proteins [6-8]. Nonhistone chromosomal pro-
teins play important roles in the interpretation of histone
code by forming chromatin remodeling complexes. Both
histones and nonhistone chromosomal proteins are
important for the regulation of gene expression, DNA rep-
lication and DNA repair. The deregulations in the expres-
sion and activity of these proteins could result in the
development of a variety of diseases such as cancer [9-13].
In a recent study, chromodomain helicase DNA binding
protein 5 (CHD5) was identified as a novel tumor sup-
pressor gene (TSG) in neuroblastoma [14]. CHD5 belongs
to a superfamily of SWI2/SNF2-related ATPases, one
major group of nonhistone chromosomal proteins.
CHD5 encodes a unique combination of functional
domains consisting of two N-terminal chromodomains,
followed by a SWI2/SNF2-like ATPase/helicase domain
and a DNA-binding domain [14]. By regulating chroma-
tin structure, CHD5 can promote the expression of p19arf
that functions to stabilize p53, the tumor suppressor inac-
tivated in more than half of human cancers [15]. CHD5 is
present at a gene locus (1p36.31) deleted in about 35% of
neuroblastoma [16]. CHD5 was previously thought to be
specifically expressed in the nervous system, but its role in
cancer in other tissues is starting to emerge [17]. CHD5
gene was found significantly deleted in glioma [18]. Apart
from gene deletion, CHD5 can be suppressed by other
mechanisms. In some cases of neuroblastoma, there are
evidence that CHD5 expression is epigenetically sup-
pressed by promoter hypermethylation [19], although
this observation was not confirmed by another study [20].
Recently, the CHD5 promoter has been found to be meth-
ylated in small subsets of breast (4.4%), colon (10%),
ovarian (15%) and glioma (17%) tumors [17,20], sug-
gesting epigenetic silencing of CHD5 by methylation may
play a partial role in tumorigenesis in these tissues. Here
we found that, in contrast to other types of cancer
reported so far, CHD5 was frequently hypermethylated in
gastric cancer (73% of tumors and 100% cell lines). The
ectopic expression of CHD5 in gastric cancer cells led to a
significant growth inhibition. This striking correlation of
the epigenetic suppression of CHD5 and gastric cancer
suggests a previously unknown relationship between this
TSG and gastric tumorigenesis.
Methods
Tissue culture and RNA/DNA extraction
All gastric cancer cell lines (AGS, Kato III, MKN28,
MKN45, SNU1, SNU16 and NCI-N87) were obtained
from Riken Gene Bank (Tsukuba, Ibaraki, Japan) and
American Type Culture Collection (ATCC, Manassas, VA,
USA). All cancer cell lines were established from carcino-
mas of gastric epithelial cells. Unless specifically indi-
cated, cells were cultured in RPMI 1640 medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum at 37°C with 5% CO2, and 95%
humidity. For pharmacological demethylation, cells were
treated with 5 M 5-aza-2'-deoxycytidine (Aza) (Sigma, St
Louis, MO, USA) for three consecutive days [21]. Aza was
replenished every 24 hours. An equivalent concentration
of the vehicle (DMSO) was used as the control. For the
primary tissues, the normal gastric tissues were defined as
non-inflammation and non-tumor tissues. All gastric car-
cinoma tissues are adenocarcinoma tissues. Total RNA
and genomic DNA was extracted using Trizol reagent (Inv-
itrogen) according to the manufacturer's instruction.
Quantitative real time RT-PCR
Reverse transcription reaction was performed using 1 g
of total RNA with Reverse Transcription System (Promega,
Madison, WI, USA). The mRNA expression levels of the
CHD5 were determined by quantitative real-time RT-PCR
SYBR Green Master Mix Kit (Applied Biosystems, Foster
City, CA, USA). Glyceraldehyde-3-phosohate dehydroge-
nase (GAPDH) was used as an internal control of RNA
integrity. Primers used for CHD5 RT-PCR were CHD5-F:
5'-AGTTCCGTGTGAGGATGAAC and CHD5-R: 5'-
TCAAGGCTGACGTGTTCAAG.
Methylation specific PCR (MSP)
Methylation status of CHD5 was determined by MSP
using bisulphate modified genomic DNA as the template.
Genomic DNA was bisulfite-treated with Zymo DNA
Modification Kit (Zymo Research, Orange, CA, USA)
according to the protocol provided. MSP was carried out
for 40 cycles with annealing temperature at 62°C, as pre-
viously described [22]. Methylation-specific primers were:
CHD5M-F: 5'-GTTCGGGGTTTAGCGTTTTC (from -525
to -506 relative to the transcription start site) and
CHD5M-R: 5'-GAAACTTAACGAACCCGAACG (from -
438 to -418), and unmethylation-specific primers were:
CHD5U-F: 5'-GGGTTTGGGGTTTAGTGTTTTT and
CHD5U-R: 5'-TCAAAACTTAACAAACCCAAACA. All
primers were confirmed previously for not amplifying any
unbisulfited DNA.Journal of Biomedical Science 2009, 16:95 http://www.jbiomedsci.com/content/16/1/95
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Bisulfite genome sequencing (BGS)
Bisulfite-treated DNA was amplified using BGS primers,
CHD5-BF: 5'-GTTGTAAATTAGATTTATAGTTTT (from -
724 to -701) and CHD5-BR: 5'-GCAAAT-
TAAAAAACTAATCCTAAA (from -324 to -301). PCR prod-
ucts were purified with Illustra GFX™ PCR and gel band
purification kit (GE Healthcare life science, Uppsala, Swe-
den) and cloned into pCR4-TOPO vector for sequencing
(Invitrogen). At least 6 colonies were randomly chosen for
plasmid extraction and sequencing analysis.
Construction of CHD5 expression plasmids
The CHD5 expression plasmid was constructed by cloning
of the full-length CHD5 open reading frame into mam-
malian expression vector pcDNA3.1. The CHD5 open
reading frame was amplified from normal stomach cDNA
using high fidelity PFU DNA polymerase (Invitrogen) and
cloned into pcDNA-TOPO4 (Invitrogen). After sequenc-
ing validation, the insert was subcloned into pcDNA3.1
with the restriction enzymes Hind III and Xba I.
Colony formation assay
Transiently transfected AGS cells with empty pcDNA3.1 or
pcDNA3.1-CHD5 were used for monolayer colony forma-
tion assay. Cells were cultured overnight in a 12-well plate
(1.0 × 105/well) and transfected with pcDNA3.1 or the
CHD5-expressing vector using lipofectamine™ 2000 (inv-
itrogen). 48 hours later, the transfectants were re-plated in
triplicate and cultured for 10-15 days in complete
RPMI1640 medium containing G418 (400 g/ml). Sur-
viving colonies were stained with Gentian Violet after
methanol fixation and colonies exceeding certain size (
50 cells) were counted. The experiments were repeated
three times.
Results
Down-regulation of CHD5 expression in gastric cancer cell 
lines
The expression of CHD5 in gastric cancer cell lines was
determined by quantitative RT-PCR. While CHD5 was
highly expressed in normal gastric tissues, its expressions
were down-regulated in all 7 gastric cancer cell lines (AGS,
Kato III, MKN28, MKN45 and NCI-N87 SNU1 and
SNU16) (Fig. 1).
Promoter hypermethylation of CHD5 in gastric cancer cell 
lines and primary gastric carcinoma tissues
A typical CpG Island (CGI) was found around CHD5
exon 1 using the following criteria: GC content >55%,
ObsCpG/ExpCpG >0.65, and length >500 bp (Fig. 2A).
The methylation status of this CGI in gastric cancer cells
was determined by methylation specific PCR (MSP). As
shown in Fig. 2B, full or partial methylation was detected
in all of 7 gastric cancer cell lines we examined. In consist-
ent with the data on gastric cell lines, the CHD5 promoter
was also methylated in the majority of primary gastric car-
cinoma tissues tested (73%, 11/15) (Fig. 2C). Impor-
tantly, methylation of the CHD5 promoter was either
undetected or weakly detectable in normal tissues adja-
cent to the tumors of the same patients and in gastric tis-
sues of normal subjects. Moreover, methylation of CHD5
promoter in gastric cancer cell lines and gastric carcinoma
tissues was confirmed by bisulfite genome sequencing
(BGS) (Fig. 2D). Taken together, CHD5 was predomi-
nately silenced in gastric cancer and promoter hypermeth-
ylation appeared to be the major mechanism of CHD5
silencing in tumorigenesis of this tissue.
Up-regulation of CHD5 expression after Aza treatment
To further confirm the promoter CGI hypermethylation-
mediated CHD5 silencing in gastric cancer cell lines,
CHD5 expressions in AGS and Kato III before and after
demethylation reagent Aza treatment were analyzed. Both
cell lines exhibit complete methylation of the CHD5 pro-
moter. CHD5 expression in these two cell lines were sig-
nificantly increased after Aza-induced demethylation of
CHD5 is down-regulated in gastric cancer cell lines Figure 1
CHD5 is down-regulated in gastric cancer cell lines. 
The expression of CHD5 in gastric cancer cell lines was 
determined by RT-PCR. GAPDH was used to normalize the 
CHD5 expression. The normal stomach tissue (stomach) 
was used as the reference. Results of quantitative real-time 
RT-PCR was shown in upper panel and the result of conven-
tional RT-PCR was shown in lower panel.Journal of Biomedical Science 2009, 16:95 http://www.jbiomedsci.com/content/16/1/95
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CHD5 promoter (Fig. 3A and 3B), demonstrating that
CHD5 is indeed epigenetically silenced in gastric cancer.
Growth inhibitory function of CHD5
The tumor suppression property of CHD5 in gastric can-
cer cells was investigated by a gain-of-function strategy.
Full open reading frame (ORF) of CHD5 was cloned into
mammalian expression vector pcDNA3.1. The effect of
ectopic CHD5 expression on the growth of gastric cancer
cells AGS was determined with monolayer colony forma-
tion assay. The forced expression of CHD5 in AGS cells
was confirmed by RT-PCR (Fig. 4A). The number of colo-
nies formed on the plate by cells over-expressing CHD5
was significantly reduced (p < 0.01) (Fig. 4B and 4C), indi-
cating that CHD5 can suppress the growth of gastric can-
cer cells.
Discussion
Over the past several years, many TSGs have been found
to be epigenetically inactivated in gastric cancer, indicat-
ing that epigenetic silencing of TSGs is one of major
molecular alterations in the process of gastric carcinogen-
esis [22-25]. In this study, CHD5 was identified as
another potential TSG whose epigenetic inactivation may
contribute to gastric carcinogenesis. It was frequently
down-regulated through promoter hypermethylation in
gastric cancer cell lines. The ectopic expression of CHD5
led to the growth inhibition of gastric cancer cells, indicat-
ing that CHD5 functions as a TSG epigenetically silenced
in gastric cancer.
Promoter hypermethylation of CHD5 in cancer has been
observed in other cancers [17,20]. However, the incidence
of CHD5 promoter methylation in gastric cancer cell lines
and tumors was found in this study to be relatively high,
compared to the frequency of CHD5 methylation in other
cancers (generally below 20%) [17,20]. Of course, more
samples should be used to confirm this result with the
same MSP primers in the following studies. Nevertheless,
our finding suggests that CHD5 inactivation might be
Pharmacological demethylation reactivates CHD5 expression  in gastric cancer cell lines Figure 3
Pharmacological demethylation reactivates CHD5 
expression in gastric cancer cell lines. A, Relative 
CHD5 expressions before and after Aza treatment were 
determined by RT-PCR as in Fig. 1. GAPDH was used to 
normalize the template amount. B, Demethylation of CHD5 
promoter in AGS cells after Aza treatment was confirmed by 
BGS as in Fig. 2D.
CHD5 promoter is hypermethylated in gastric cancer Figure 2
CHD5 promoter is hypermethylated in gastric can-
cer. A, CHD5 has a typical CpG island (CGI) around its 
exon 1. CGI was plotted by GeneTool program. The posi-
tions of BGS and MSP primers were indicated as arrows. B, 
The methylation status of CHD5 promoter in gastric cancer 
cells was determined by methylation specific PCR. M: methyl-
ation; U: unmethylation. C, The methylation status of CHD5 
promoter in primary gastric cancer tissues was determined 
by methylation specific PCR as in B. Normal gastric tissues 
and adjacent non-tumor tissues were used as controls. N1 
and N2 are normal gastric tissues. T1 and T2 indicate gastric 
carcinoma tissues while A1 and A2 represent adjacent non-
tumor tissues. Represented results were shown. D, Methyla-
tion of CHD5 promoter in gastric cancer cell lines and pri-
mary gastric carcinoma tissues was confirmed by BGS. Each 
circle indicates one CpG site and circles filled in black repre-
sent methylated CpG sites. One row of circles represents a 
single colony.Journal of Biomedical Science 2009, 16:95 http://www.jbiomedsci.com/content/16/1/95
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mediated by different mechanisms in different tissues.
Whereas CHD5 is inactivated through copy number
abnormality in various cancers [15,16], comparative
genomic hybridization (CGH) indicated that 1p36, the
CHD5-containing gene locus, is not significantly imbal-
anced in gastric cancers [26]. Instead, as shown in this
study, CHD5 appears to be silenced predominately by
promoter hypermethylation in gastric cancer.
There is growing evidence that hypermethylation of TSG
promoter represents one of major molecular alterations in
cancer development. The high incidence of CHD5 pro-
moter hypermethylation in gastric cancer can be explored
not only as a gastric cancer diagnosis but also prognosis
prediction. To this end, it is important to characterize the
CHD5 promoter methylation in association with clinical
characteristics, such as age, gender, H. pylori infection,
tumor grade, Lauren classification and differentiation.
Given that the high heterogeneity of primary gastric carci-
noma tissues, methylation analyses with higher resolu-
tion such as quantitative methylation specific analysis
using sequenom or Taqman real-time PCR will be helpful
to assess whether CHD5 promoter methylation is useful
for early gastric cancer detection and prognosis predic-
tion.
Although promoter methylation frequently inactivates
CHD5 in gastric cancer cell lines, we cannot exclude the
presence of other mechanisms for the loss function of
CHD5 in gastric cancer. CHD5 expression is extremely
low in MKN28 and SNU16 (Fig. 1), however, the pro-
moter of CHD5 was only partially methylated in these
two cell lines (Fig. 2B), indicating that other mechanisms
may be responsible for the silencing of CHD5 in some of
gastric cancer cell lines.
Conclusion
CHD5 was frequently down-regulated through promoter
hypermethylation in gastric cancer cells. The ectopic
expression of CHD5 led to growth inhibition of gastric
cancer cells, indicating that CHD5 functions as a tumor
suppressor gene epigenetically silenced in gastric cancer.
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